JP Morgan raised the price target for the Bausch Health Companies Inc. (NYSE:BHC) stock to ‘an Overweight’. The rating was released on June 13, 2023, according to finviz. The research report from RBC Capital Mkts has upgraded the stock from Sector Perform to Outperform, with a price target set at $42. The stock was downgraded by Piper Sandler, who disclosed in a research note on January 22, 2021, from Overweight to Neutral and set the price objective to $30. In their research brief published September 17, 2020, BofA Securities analysts upgraded the Bausch Health Companies Inc.
